- Home
- PVL vs CUE Comparison
PVL vs CUE Comparison
Compare PVL & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PVL | CUE |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 27.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PVL | CUE |
|---|---|---|
| Price | $1.81 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 135.3K | ★ 442.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | N/A | ★ 35.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,287,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $26.85 | ★ N/A |
| Revenue Growth | N/A | ★ 69.16 |
| 52 Week Low | $1.30 | $0.23 |
| 52 Week High | $2.04 | $1.05 |
Technical Indicators
Market Signals| Indicator | PVL | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 56.88 | 39.65 |
| Support Level | $1.72 | $0.27 |
| Resistance Level | $1.88 | $0.36 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 65.63 | 14.60 |
Price Performance
Historical ComparisonAbout PVL Permianville Royalty Trust Trust Units
Permianville Royalty Trust is a statutory trust which holds net profits interests in the profits from the sale of oil and natural gas production from non-operated assets of both conventional properties in the States of Texas, Louisiana, and New Mexico as well as unconventional assets in the Permian and Haynesville basins.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.